Cargando…

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)

Objective: While several drugs have been linked to acute pancreatitis (AP), the AP-related risk of most drugs remains unclear. This study investigated the risk factors for drug-induced AP by analyzing a large dataset from the FDA Adverse Event Reporting System (FAERS). Methods: The reporting odds ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, Mao, Wei, Liu, Dan, Hu, Bin, Lin, Xiaofang, Ran, Jie, Li, Xingxing, Hu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690789/
https://www.ncbi.nlm.nih.gov/pubmed/38044938
http://dx.doi.org/10.3389/fphar.2023.1231320
_version_ 1785152596805156864
author Zhang, Lin
Mao, Wei
Liu, Dan
Hu, Bin
Lin, Xiaofang
Ran, Jie
Li, Xingxing
Hu, Jing
author_facet Zhang, Lin
Mao, Wei
Liu, Dan
Hu, Bin
Lin, Xiaofang
Ran, Jie
Li, Xingxing
Hu, Jing
author_sort Zhang, Lin
collection PubMed
description Objective: While several drugs have been linked to acute pancreatitis (AP), the AP-related risk of most drugs remains unclear. This study investigated the risk factors for drug-induced AP by analyzing a large dataset from the FDA Adverse Event Reporting System (FAERS). Methods: The reporting odds ratios (ROR) were used to assess the reports of drug-induced AP from the first quarter of 2004 to the second quarter of 2022. Single-factor, LASSO, and multi-factor regression analysis were performed to explore drug-related AP-related risk factors. Bonferroni correction was applied for the multiple comparisons performed. Results: A total of 264 drugs associated with AP, including antineoplastic drugs (35/264), antidiabetic drugs (28/264), antibacterial drugs (24/264), immunomodulatory drugs (11/264), antipsychotic drugs (6/264), and other drugs (160/264) were retrieved. Multi-factor analysis showed that males, age 41–54 years old, and 36 drugs, including Tigecycline, were risk factors for drug-related AP. The median time to drug-related AP onset was 31 days (interquartile range [IQR] 7–102 days) and about 75% of adverse events occurred within 100 days. Conclusion: These findings may help clinicians to identify drug-related AP at the early stage and can be used to inform future studies of drug-related AP pathogenesis.
format Online
Article
Text
id pubmed-10690789
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106907892023-12-02 Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) Zhang, Lin Mao, Wei Liu, Dan Hu, Bin Lin, Xiaofang Ran, Jie Li, Xingxing Hu, Jing Front Pharmacol Pharmacology Objective: While several drugs have been linked to acute pancreatitis (AP), the AP-related risk of most drugs remains unclear. This study investigated the risk factors for drug-induced AP by analyzing a large dataset from the FDA Adverse Event Reporting System (FAERS). Methods: The reporting odds ratios (ROR) were used to assess the reports of drug-induced AP from the first quarter of 2004 to the second quarter of 2022. Single-factor, LASSO, and multi-factor regression analysis were performed to explore drug-related AP-related risk factors. Bonferroni correction was applied for the multiple comparisons performed. Results: A total of 264 drugs associated with AP, including antineoplastic drugs (35/264), antidiabetic drugs (28/264), antibacterial drugs (24/264), immunomodulatory drugs (11/264), antipsychotic drugs (6/264), and other drugs (160/264) were retrieved. Multi-factor analysis showed that males, age 41–54 years old, and 36 drugs, including Tigecycline, were risk factors for drug-related AP. The median time to drug-related AP onset was 31 days (interquartile range [IQR] 7–102 days) and about 75% of adverse events occurred within 100 days. Conclusion: These findings may help clinicians to identify drug-related AP at the early stage and can be used to inform future studies of drug-related AP pathogenesis. Frontiers Media S.A. 2023-11-17 /pmc/articles/PMC10690789/ /pubmed/38044938 http://dx.doi.org/10.3389/fphar.2023.1231320 Text en Copyright © 2023 Zhang, Mao, Liu, Hu, Lin, Ran, Li and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Lin
Mao, Wei
Liu, Dan
Hu, Bin
Lin, Xiaofang
Ran, Jie
Li, Xingxing
Hu, Jing
Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
title Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
title_full Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
title_fullStr Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
title_full_unstemmed Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
title_short Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
title_sort risk factors for drug-related acute pancreatitis: an analysis of the fda adverse event reporting system (faers)
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690789/
https://www.ncbi.nlm.nih.gov/pubmed/38044938
http://dx.doi.org/10.3389/fphar.2023.1231320
work_keys_str_mv AT zhanglin riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT maowei riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT liudan riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT hubin riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT linxiaofang riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT ranjie riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT lixingxing riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers
AT hujing riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers